{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T21:30:12Z","timestamp":1777930212698,"version":"3.51.4"},"reference-count":0,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2009,4,27]],"date-time":"2009-04-27T00:00:00Z","timestamp":1240790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2009,4,27]],"date-time":"2009-04-27T00:00:00Z","timestamp":1240790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Onkologie"],"abstract":"<jats:p>Die tumorassoziierte chronische An\u00e4mie tritt als Komplikation bei Malignomen auf und verursacht Symptome, welche die Lebensqualit\u00e4t beeintr\u00e4chtigen und oft Bluttransfusionen erforderlich machen. In dieser klinischen Studie behandelten wir 13 Patienten mit tumorassoziierter chronischer An\u00e4mie und multiplem Myelom dreimal w\u00f6chentlich mit rekombinantem humanem Erythropoietin (rHuEPO). Elf Patienten sprachen auf die Therapie mit einer ausreichenden Erh\u00f6hung ihrer H\u00e4moglobinwerte und der Korrektur des an\u00e4mischen Krankheitsbildes an. Bei einem Patienten blieb die Therapie erfolglos, er mu\u00dfte die Behandlung wegen Transfusionsbed\u00fcrftigkeit vorzeitig abbrechen. Die unter rHuEPO-Therapie erhobenen Parameter des Eisenstoffwechsels deuteten auf eine gesteigerte H\u00e4moglobinsynthese hin. Die klinischen Symptome der An\u00e4mie verschwanden bei den erfolgreich behandelten Patienten; die meisten von ihnen berichteten \u00fcber gesteigertes subjektives Wohlbefinden. Unerw\u00fcnschte Nebenwirkungen der Therapie, insbesondere Episoden von Bluthochdruck, wurden bei keinem einzigen Patienten beobachtet.<\/jats:p>","DOI":"10.1159\/000216719","type":"journal-article","created":{"date-parts":[[2009,4,29]],"date-time":"2009-04-29T10:05:34Z","timestamp":1240999534000},"page":"46-49","source":"Crossref","is-referenced-by-count":3,"title":["Erythropoietin-Behandlung der tumorassoziierten An\u00e4mie bei Patienten mit multiplem Myelom"],"prefix":"10.1159","author":[{"given":"H.","family":"Ludwig","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Fritz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Kotzmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Gisslinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2009,4,27]]},"container-title":["Onkologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/216719","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000216719","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:07:00Z","timestamp":1777680420000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000216719"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4,27]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1159\/000216719","archive":["Portico"],"relation":{},"ISSN":["0378-584X","1423-0240"],"issn-type":[{"value":"0378-584X","type":"print"},{"value":"1423-0240","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4,27]]}}}